Emphysema

1,218,672views

Emphysema

Watch later

Watch later

Coronary artery disease: Clinical
Inflammatory bowel disease: Pathology review
Crohn disease
Ulcerative colitis
Inflammatory bowel disease: Clinical
Macrocytic anemia: Pathology review
Anemia: Clinical
Extrinsic hemolytic normocytic anemia: Pathology review
Microcytic anemia: Pathology review
Sideroblastic anemia
Autoimmune hemolytic anemia
Iron deficiency anemia
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Anemia of chronic disease
Folate (Vitamin B9) deficiency
Pancreatitis: Pathology review
Pancreatitis: Clinical
Acute pancreatitis
Chronic pancreatitis
Superior mesenteric artery syndrome
Diverticulosis and diverticulitis
Diverticular disease: Pathology review
Diverticular disease: Clinical
Appendicitis: Clinical
Appendicitis
Appendicitis: Pathology review
Irritable bowel syndrome
Anatomy of the abdominal viscera: Large intestine
Vitamin B12 deficiency
Myocardial infarction
ECG cardiac infarction and ischemia
Clot retraction and fibrinolysis
Platelet plug formation (primary hemostasis)
Erythropoietin
Coagulation (secondary hemostasis)
Atrial fibrillation
Anticoagulants: Warfarin
Heart failure
Heart failure: Pathology review
Heart failure: Clinical
Ventricular fibrillation
Ventricular tachycardia
Class III antiarrhythmics: Potassium channel blockers
Atrial flutter
Ventricular arrhythmias: Pathology review
Supraventricular arrhythmias: Pathology review
Acute kidney injury: Clinical
Kidney stones: Pathology review
Kidney stones
Glomerular filtration
Long QT syndrome and Torsade de pointes
Hyperkalemia
Hyperkalemia: Clinical
Chronic kidney disease
Chronic kidney disease: Clinical
Hyperphosphatemia
Hypercalcemia
Kidney stones: Clinical
Renal failure: Pathology review
Diabetes mellitus: Clinical
Metabolic acidosis
Class I antiarrhythmics: Sodium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class II antiarrhythmics: Beta blockers
Positive inotropic medications
Hyponatremia: Clinical
Hyponatremia
Hypernatremia: Clinical
Hypernatremia
Chronic obstructive pulmonary disease (COPD): Clinical
Obstructive lung diseases: Pathology review
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Emphysema
Pulmonary hypertension
Cor pulmonale
Chronic bronchitis
Muscarinic antagonists
Asthma: Clinical
Asthma
Pulmonary embolism
Deep vein thrombosis and pulmonary embolism: Pathology review
Venous thromboembolism: Clinical
Pneumonia: Pathology review
Pneumonia
Pneumonia: Clinical
Ventilation-perfusion ratios and V/Q mismatch
Shock: Clinical
Shock: Pathology review
Shock
Factor V Leiden
Anticoagulants: Heparin
Hyperthyroidism medications
Hyperthyroidism: Pathology review
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Hypothyroidism: Pathology review
Hypothyroidism medications
Pheochromocytoma
Adrenal masses: Pathology review
Renal artery stenosis
Hyperaldosteronism
Respiratory distress syndrome: Pathology review
Acute respiratory distress syndrome: Clinical
Diabetes insipidus and SIADH: Pathology review
Pericardial disease: Clinical
Dementia and delirium: Clinical
Dementia with Lewy bodies
Alzheimer disease
Parkinson disease
Anti-parkinson medications
Traumatic brain injury: Clinical
Concussion and traumatic brain injury
Brown-Sequard Syndrome
Cauda equina syndrome
Meningitis
Myasthenia gravis
Multiple sclerosis
Stroke: Clinical
Cerebral vascular disease: Pathology review
Alcohol use disorder
Seizures: Clinical

Transcript

Watch video only

Emphysema means “inflate or swell”, which makes sense because in the lungs of people with emphysema, the alveolar air sacs, which are the thin walled air spaces at the ends of the airways where oxygen and carbon dioxide are exchanged, become damaged or destroyed.

The alveoli permanently enlarge and lose elasticity, and as a result, individuals with emphysema typically have difficulty with exhaling, which depends heavily on the ability of lungs to recoil like elastic bands.

Emphysema’s actually lumped under the umbrella of chronic obstructive pulmonary disease (or COPD), along with chronic bronchitis.

The two differ in that chronic bronchitis is defined by clinical features, like the productive cough, whereas emphysema is defined by structural changes, mainly enlargement of the air spaces.

That being said, they almost always coexist, probably because they share the same major cause—smoking.

With COPD, the airways become obstructed, the lungs don’t empty properly, and that leaves air trapped inside the lungs.

For that reason, the maximum amount of air people with COPD can breath out in a single breath, known as the FVC, or forced vital capacity, is lower.

This reduction is especially noticeable in the first second of air breathed out in a single breath, called FEV1forced expiratory volume (in one second), which typically is reduced even more than the FVC.

A useful metric therefore is the FEV1 to FVC ratio, which, since the FEV1 goes down even more than FVC, causes the FEV1 to FVC ratio to go down as well.

Alright so say normally your FVC is 5 L, and your FEV1 is 4 L, your FEV1 to FVC ratio would end up being 80%.

Now, someone with COPD’s FVC might be 4 L instead, which is lower than normal, but the volume of air that he or she can expire in the first second is only 2 L, so not only are both these values lower, but their ratio is lower as well—and this is a hallmark of COPD.

All that had to do with air breathed out right? Conversely, for air going in, the TLC, or total lung capacity, which is the maximum volume of air that can be taken in or inspired into the lungs, is actually often often higher because of the air trapping.

Alright, so emphysema is a form of COPD, that’s based on structural changes in the lung, specifically a destruction of the alveoli.

Normally, though oxygen flows out of the alveoli and into the blood while carbon dioxide makes the reverse commute, but when the lung tissue is exposed to irritants like cigarette smoke, it triggers an inflammatory reaction that upsets the delicate alveolar walls and affects the flow of gases.

Inflammatory reactions attract various immune cells which release inflammatory chemicals like leukotriene B4, IL-8, and TNF alpha, as well as proteases, like elastases and collagenases.

These proteases break down key structural proteins in the connective tissue layer like collagen, as well as elastin, which is a protein that gives the tissue elasticity, and this leads to the problems seen in emphysema.

In healthy lungs, during exhalation, air whizzes through the airways with high velocity, creating a low pressure environment in the airway.

This is due to the Bernoulli principle, where, as a fluid—which includes air—moves at higher velocity, it must have lower pressure. Now this lower pressure tends to pull the tiny airway inward.

Strong healthy airway walls full of elastin can withstand that pressure and don’t collapse; they hold the airway open and allow air to fully escape during exhalation.

With emphysema though, that elastin’s lost, which makes the airway walls weak and allow that low pressure system to pull the walls inward and collapse during exhalation.

This ultimately leads to air-trapping because the collapsed airway traps a tiny bit of air distal to the point of collapse.

Also, this loss of elastin makes the lungs more compliant, meaning that when air blows into them, they easily expand and then hold onto that air instead of expelling it during exhalation, and so the lungs start to look like large thin plastic bags.

The loss of elastin also leads to a breakdown of the thin alveolar walls called septa.

Without these walls, neighboring alveoli coalesce into larger and larger air spaces, which means the surface area available for gas exchange is reduced (relative to the expanding volume), which affects oxygen and carbon dioxide levels.

This process all happens in the acinus, which is the endings of the lung airways where those clusters of alveoli are located.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease" American Journal of Respiratory and Critical Care Medicine (2013)
  6. "Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology" European Respiratory Journal (2005)
  7. "Screening for Chronic Obstructive Pulmonary Disease" JAMA (2016)
  8. "Endocarditis" JAMA (2018)
  9. "Infective endocarditis" The Lancet (2016)
  10. "Endocardite infectieuse. Épidémiologie, physiopathologie et anatomopathologie" La Presse Médicale (2019)